Pharmacoeconomic review report: Sodium zirconium cyclosilicate (Lokelma) (AstraZeneca Canada Inc.) indication : for the treatment of hyperkalemia in adult patients.
The sponsor assumed that patients who started treatment on SZC would move on to BSC if they discontinued their initial treatment. Reinitiation was allowed after the first 28-day period and prior to RRT initiation. Both CKD and HF progression were based on the literature, and a mixed-effects regressi...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa, ON
Canadian Agency for Drugs and Technologies in Health
2020, May 2020
|
| Edition: | Version: final |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references